BioAge Labs (NASDAQ:BIOA) Trading 4.6% Higher – Here’s What Happened

Posted by Stanley Muller on May 19th, 2026

BioAge Labs, Inc. (NASDAQ:BIOA – Get Free Report) was up 4.6% during mid-day trading on Tuesday . The company traded as high as $16.08 and last traded at $16.04. Approximately 105,106 shares were traded during trading, a decline of 83% from the average daily volume of 619,233 shares. The stock had previously closed at $15.34.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Morgan Stanley set a $23.00 price objective on shares of BioAge Labs in a research note on Wednesday, February 4th. BTIG Research initiated coverage on BioAge Labs in a research report on Wednesday, May 13th. They issued a “buy” rating and a $40.00 price target for the company. Citigroup upped their price objective on BioAge Labs from $15.00 to $52.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Needham & Company LLC began coverage on BioAge Labs in a research report on Friday, March 27th. They set a “buy” rating and a $50.00 price objective on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a report on Friday, April 24th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $45.00.

Check Out Our Latest Analysis on BIOA

BioAge Labs Stock Up 7.6%

The business has a 50-day moving average price of $18.05 and a 200-day moving average price of $15.93. The firm has a market capitalization of $733.65 million, a price-to-earnings ratio of -6.88 and a beta of 0.99.

BioAge Labs (NASDAQ:BIOA – Get Free Report) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.52) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.19. BioAge Labs had a negative return on equity of 29.40% and a negative net margin of 871.75%.The firm had revenue of $2.77 million during the quarter. On average, equities research analysts forecast that BioAge Labs, Inc. will post -2.59 earnings per share for the current year.

Hedge Funds Weigh In On BioAge Labs

Hedge funds and other institutional investors have recently modified their holdings of the stock. CWM LLC grew its position in BioAge Labs by 39.9% during the 4th quarter. CWM LLC now owns 3,693 shares of the company’s stock worth $49,000 after purchasing an additional 1,053 shares during the last quarter. Price T Rowe Associates Inc. MD raised its holdings in shares of BioAge Labs by 24.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,808 shares of the company’s stock worth $196,000 after buying an additional 2,917 shares during the last quarter. Barclays PLC lifted its stake in shares of BioAge Labs by 9.3% during the fourth quarter. Barclays PLC now owns 37,780 shares of the company’s stock worth $500,000 after buying an additional 3,222 shares during the period. Bank of America Corp DE lifted its stake in shares of BioAge Labs by 46.3% during the third quarter. Bank of America Corp DE now owns 11,119 shares of the company’s stock worth $65,000 after buying an additional 3,517 shares during the period. Finally, Russell Investments Group Ltd. purchased a new stake in shares of BioAge Labs during the third quarter valued at $27,000.

About BioAge Labs

(Get Free Report)

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.